S. 898 · 117th Congress
Fair Accountability and Innovative Research Drug Pricing Act of 2021
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
BaldwinSponsor5 cosponsors · 1 D, 3 R, 1 I
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Fair Accountability and Innovative Research Drug Pricing Act of 20 21
What it does: CRS summary · Introduced in Senate · Mar 23, 2021
Fair Accountability and Innovative Research Drug Pricing Act of 2021
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Fair Accountability and Innovative Research Drug Pricing Act of 2021
Latest action (Mar 23, 2021): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Mar 23, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.